A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Sponsor: AstraZeneca
A PHASE3 clinical study on Atherosclerosis, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 14 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Apr 2019 — Jan 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Bengbu, China , Changsha, China , Chongqin, China , Guangzhou, China , Haerbin, China , Nanchang, China , Nanjing, China , Ningbo, China , Shanghai, China and 5 more locations